[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.136.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

August 2019 - April 2015

Decade

Year

Issue

April 2019, Vol 5, No. 4, Pages 451-580

Original Investigation

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade

Abstract Full Text
JAMA Oncol. 2019;5(4):471-478. doi:10.1001/jamaoncol.2018.5801

This case series study assesses the prevalence of microsatellite instability–high or mismatch repair–deficient prostate cancer and the clinical benefit of immune checkpoint blockade with anti–PD-1/PD-L1 therapy in this molecularly defined population.

Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis

Abstract Full Text
JAMA Oncol. 2019;5(4):480-489. doi:10.1001/jamaoncol.2018.6720

This systematic review and meta-analysis examines randomized clinical trials to assess the safety and efficacy of medications used for patients with gastrointestinal and pancreatic neuroendocrine tumors.

First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis

Abstract Full Text
JAMA Oncol. 2019;5(4):491-496. doi:10.1001/jamaoncol.2018.7086

This cost-effectiveness analysis compares nivolumab plus ipilimumab vs sunitinib to examine whether the drug combination is cost-effective from a US payer perspective as a first-line treatment for intermediate- and poor-risk patients with metastatic renal cell carcinoma.

Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices

Abstract Full Text
JAMA Oncol. 2019;5(4):497-505. doi:10.1001/jamaoncol.2018.6437

This cohort study describes prevalence rates of infection with hepatitis B virus, hepatitis C virus, and HIV among patients with newly diagnosed cancer in academic and community oncology practices.

Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(4):506-513. doi:10.1001/jamaoncol.2018.6727

This randomized clinical trial of patients with stage I gastric cancer examines whether long-term survival among patients undergoing laparoscopic distal gastrectomy is noninferior to that among patients undergoing open distal gastrectomy.

Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors

Abstract Full Text
JAMA Oncol. 2019;5(4):514-522. doi:10.1001/jamaoncol.2018.6477

This case-control study evaluates the enrichment of germline pathogenic variants in the mendelian cancer predisposition DNA repair genes in patients with testicular germ cell tumors compared with healthy controls.

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

Abstract Full Text
open access
JAMA Oncol. 2019;5(4):523-528. doi:10.1001/jamaoncol.2018.6760

This cross-sectional study assesses the frequency and distribution of positive germline variants in patients with prostate cancer and evaluates the usefulness of current practice guidelines in recognizing individuals with prostate cancer who would benefit from diagnostic genetic testing.

Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis

Abstract Full Text
JAMA Oncol. 2019;5(4):529-536. doi:10.1001/jamaoncol.2018.5904

This systematic review and meta-analysis examine randomized clinical trials to assess whether immunotherapy treatments for advanced cancer are less effective in female patients.

Long-term Somatic Disease Risk in Adult Danish Cancer Survivors

Abstract Full Text
JAMA Oncol. 2019;5(4):537-545. doi:10.1001/jamaoncol.2018.7192

This nationwide, population-based cohort-cohort study of compares the temporal pattern of hospitalizations for medically verified incident somatic disease between cancer survivors and cancer-free people.

Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

Abstract Full Text
online only
JAMA Oncol. 2019;5(4):e185896. doi:10.1001/jamaoncol.2018.5896

This case series of patients with rectal cancer compares outcomes between those who had a clinical complete response to neoadjuvant therapy and agreed to a watch-and-wait strategy and those who underwent total mesorectal excision and had a pathologic complete response at resection.

Brief Report

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Abstract Full Text
JAMA Oncol. 2019;5(4):546-550. doi:10.1001/jamaoncol.2018.5441

This phase 2, open-label, interventional study examined the safety and efficacy of pembrolizumab for patients with advanced, metastatic esophageal carcinoma that has progressed after 2 or more lines of systemic therapy.

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status

Abstract Full Text
JAMA Oncol. 2019;5(4):551-555. doi:10.1001/jamaoncol.2018.4942

This cohort study investigates possible mechanisms underlying primary resistance to immune checkpoint inhibitors of metastatic colorectal cancers displaying microsatellite instability or mismatch repair deficiency.

Research Letter

Use, Safety, and Efficacy of Single-Patient Use of the US Food and Drug Administration Expanded Access Program

Abstract Full Text
open access
JAMA Oncol. 2019;5(4):570-572. doi:10.1001/jamaoncol.2018.7002

This study assesses the outcomes of single-patient use of the US Food and Drug Administration Expanded Access program.

Review

Parallels Between Low-Risk Prostate Cancer and Thyroid Cancer: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(4):556-564. doi:10.1001/jamaoncol.2018.5321

This narrative review describes the parallels and differences between prostate cancer and thyroid cancer regarding screening, diagnosis, risk stratification, and considerations for active surveillance.

JAMA Network Insights

Treatment of Desmoid Tumors in 2019

Abstract Full Text
JAMA Oncol. 2019;5(4):567-568. doi:10.1001/jamaoncol.2018.6449

This article describes an approach to active surveillance and treatment of desmoid tumor (aggressive fibromatosis).

JAMA Oncology Clinical Challenge

Erythematous Macular Eruption in an Older Woman

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(4):565-566. doi:10.1001/jamaoncol.2018.5317

A white woman in her 70s with Alzheimer disease presented with a high hemoglobin level and red blood cell count as well as erythematous macular eruption over the trunk and limbs. What is your diagnosis?

Viewpoint

Investigating Potential Bias in Patient-Reported Outcomes in Open-label Cancer Trials

Abstract Full Text
JAMA Oncol. 2019;5(4):457-458. doi:10.1001/jamaoncol.2018.6205

This Viewpoint highlights the importance of potential bias in patient-reported outcomes in open-label cancer trials and points to areas of research that could address this challenge.

Time for Advance Care Planning Discussions During Transitions in Care in Cancer Clinical Trials

Abstract Full Text
JAMA Oncol. 2019;5(4):459-460. doi:10.1001/jamaoncol.2018.6872

This Viewpoint suggests that advance care planning discussions can be initiated during transitions in care from cancer clinical trials.

Evaluating New Rules on Transparency in Cancer Research and Drug Development

Abstract Full Text
JAMA Oncol. 2019;5(4):461-462. doi:10.1001/jamaoncol.2018.7093

This Viewpoint evaluates new transparency policies in cancer research and drug development.

Invited Commentary

Microsatellite Instability as an Emerging Biomarker for Checkpoint Inhibitor Response in Advanced Prostate Cancer

Abstract Full Text
JAMA Oncol. 2019;5(4):478-479. doi:10.1001/jamaoncol.2018.5789

Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors

Abstract Full Text
JAMA Oncol. 2019;5(4):489-490. doi:10.1001/jamaoncol.2018.6694
Editor's Note

Is Watch-and-Wait Ready for Prime Time?It Depends on Priming of the Multidisciplinary Care Team

Abstract Full Text
free access online only
JAMA Oncol. 2019;5(4):e185895. doi:10.1001/jamaoncol.2018.5895
Cancer Care Chronicles

Honesty in Medicine—An Approach to Patients With Cancer Who Initially Reject Conventional Treatment

Abstract Full Text
JAMA Oncol. 2019;5(4):463-464. doi:10.1001/jamaoncol.2018.7164

This essay describes one physician’s approach to patients with cancer who question their initial decision to forgo conventional definitive treatment.

Poetry and Oncology

Pentito

Abstract Full Text
JAMA Oncol. 2019;5(4):580. doi:10.1001/jamaoncol.2018.6869
Comment & Response

Role of Monthly High-Dose Vitamin D Supplementation in Cancer Prevention

Abstract Full Text
JAMA Oncol. 2019;5(4):572. doi:10.1001/jamaoncol.2018.7214

Role of Monthly High-Dose Vitamin D Supplementation in Cancer Prevention—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(4):572-573. doi:10.1001/jamaoncol.2018.7233

Techniques and Thresholds for Quantifying Circulating Tumor Cells in Breast Cancer

Abstract Full Text
JAMA Oncol. 2019;5(4):573-574. doi:10.1001/jamaoncol.2018.7217

Techniques and Thresholds for Quantifying Circulating Tumor Cells in Breast Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(4):574. doi:10.1001/jamaoncol.2018.7236

Level of Evidence and Ethical Considerations for Locoregional Treatments in Metastatic Cervical Cancer

Abstract Full Text
JAMA Oncol. 2019;5(4):574-575. doi:10.1001/jamaoncol.2018.5096

Level of Evidence and Ethical Considerations for Locoregional Treatments in Metastatic Cervical Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(4):575-576. doi:10.1001/jamaoncol.2019.0028

CHEK2 Alleles Predispose to Renal Cancer in Poland

Abstract Full Text
JAMA Oncol. 2019;5(4):576. doi:10.1001/jamaoncol.2019.0022

CHEK2 Alleles Predispose to Renal Cancer in Poland—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(4):576-577. doi:10.1001/jamaoncol.2019.0025

Analyzing Frequently Mutated Genes and the Association With Tumor Mutation Load

Abstract Full Text
JAMA Oncol. 2019;5(4):577. doi:10.1001/jamaoncol.2019.0127

Tumor Mutation Load and Frequently Mutated Genes in Gastric Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(4):577-578. doi:10.1001/jamaoncol.2019.0135

Omitted Disclosures of Potential Conflicts of Interest in Articles Published in JAMA Oncology

Abstract Full Text
JAMA Oncol. 2019;5(4):578-579. doi:10.1001/jamaoncol.2019.0235
Correction

Incomplete Conflict of Interest Disclosures

Abstract Full Text
free access
JAMA Oncol. 2019;5(4):579. doi:10.1001/jamaoncol.2019.0286

Errors in Author Affiliations and Additional Contributions

Abstract Full Text
free access
JAMA Oncol. 2019;5(4):579. doi:10.1001/jamaoncol.2019.0220

Affiliation Added

Abstract Full Text
free access
JAMA Oncol. 2019;5(4):579. doi:10.1001/jamaoncol.2019.0705

Omission in Additional Information

Abstract Full Text
free access
JAMA Oncol. 2019;5(4):580. doi:10.1001/jamaoncol.2019.0708

Misspelled Author Name

Abstract Full Text
free access
JAMA Oncol. 2019;5(4):580. doi:10.1001/jamaoncol.2019.0811
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(4):452. doi:10.1001/jamaoncol.2018.4750
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2019;5(4):451. doi:10.1001/jamaoncol.2018.4749
×